CCM
GPCR icon

Cinctive Capital Management’s Structure Therapeutics GPCR Stock Holding History

Cinctive Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
40,877
+32,163
+369% +$1.42M 0.08% 261
2026
Q1 		$420K Buy
+8,714
New +$596K 0.03% 308
2025
Q1 		– Sell
-9,065
Closed -$246K – 375
2024
Q4 		$246K Sell
9,065
-23,029
-72% -$817K 0.01% 337
2024
Q3 		$1.41M Buy
32,094
+16,883
+111% +$653K 0.08% 259
2024
Q2 		$597K Buy
+15,211
New +$625K 0.03% 343

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Cinctive Capital Management's GPCR Position: Q2 2026 in Review

Cinctive Capital Management increased its Structure Therapeutics (GPCR) stake by 369% in Q2 2026, buying an estimated $1.42M and bringing the position to 40,877 shares worth $2.19M. The position accounts for 0.08% of the portfolio, ranked #261.

Cinctive Capital Management first reported a position in GPCR in Q2 2024 and has held it in 5 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Cinctive Capital Management held 40,877 shares of Structure Therapeutics worth $2.19M as of Q2 2026.
  • Cinctive Capital Management bought 32,163 Structure Therapeutics shares in Q2 2026, an estimated $1.42M.
  • Structure Therapeutics made up 0.08% of Cinctive Capital Management's portfolio in Q2 2026, its #261 holding.
  • Cinctive Capital Management first reported a position in Structure Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.